Exscientia plc (Nasdaq: EXAI) announced today that Sumitomo Pharma Co, Ltd. (“Sumitomo Pharma”) announced the initiation of a Phase 1 clinical trial of DSP-2342 in the United States. DSP-2342 is a highly selective, bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity and broad potential in psychiatric disorders. It is the third molecule developed on Exscientia’s AI-assisted drug discovery platform through a collaboration with Sumitomo Pharma, also known as “Design as a Service” (DaaS).
“With three AI-generated developmental compounds developed for Sumitomo Pharma and our own growing pipeline, we have repeatedly validated our approach and are on track to realize our vision of coding and automating pharmaceutical R&D,” reports Andrew Hopkins, Founder and Chief Executive Officer of Exscientia. “With the help of AI, we are creating a much more efficient process for the design and development of differentiated drug candidates. We are convinced that in the future all new therapies will be developed with the help of AI.”
Following the successful conclusion of the DaaS partnership for DSP-2342, Sumitomo Pharma holds all further rights to the development, commercialization and commercial exploitation of the compound. However, Exscientia retains ownership or beneficial interest in any compound in its portfolio that is not part of the original agreement with Sumitomo Pharma. These include EXS21546, an A2Areceptor antagonist, GTAEXS617, a CDK7 inhibitor, and EXS4318, a selective PKC-theta inhibitor being evaluated by Bristol Myers Squibb for use in inflammatory diseases. In addition, two other proprietary precision oncology candidates were recently announced: EXS74539, an LSD1 inhibitor, and EXS73565, a MALT1 protease inhibitor, both of which are currently being investigated in IND/CTA studies.
About Exscientia
Exscientia is an AI-powered precision medicine company dedicated to discovering, designing and developing the best possible drugs in the fastest and most effective way using AI. Exscientia has developed the first functional precision oncology platform that has successfully guided therapy choices and improved patient outcomes in a prospective clinical intervention study. She is also advancing small molecule compounds developed with the help of AI to clinical development. Our internal pipeline is focused on applying our precision medicine platform in oncology, while our partnered pipeline is expanding our approach to other therapeutic areas. As pioneers of a new approach to drug development, we believe that the best ideas in science can be quickly translated into the best therapies for patients. Visit us at www.exscientia.ai or follow us on Twitter: @exscientiaAI.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, related to the performance of Exscientia’s generative AI platform and the discovery and development of candidate molecules, timing, progress and data from preclinical studies and clinical trials of Sumitomo Pharma’s and Exscientia’s product candidates, which they wholly or partially own. Any statement that describes Exscientia’s goals, plans, expectations, intentions or beliefs is a forward-looking statement and should be considered a risky statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those relating to: the impact that macroeconomic conditions and geopolitical events could have on the Company’s business; the initiation, scope and progress of planned and ongoing preclinical studies by Exscientia and its partners and aspects related to their costs; clinical, scientific, regulatory and technological developments; the process of discovering, developing and commercializing product candidates that are safe and effective for administration as human therapeutics; and efforts to build a business around such product candidates. Considering these risks and uncertainties, as well as the other risks and uncertainties described in the “Risk Factors” section and other sections of Exscientia’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850) and as detailed in other filings Exscientia periodically files with the SEC (available at https://www.sec.gov/), the events and circumstances described in the forward-looking statements could not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied. Although Exscientia’s forward-looking statements represent management’s beliefs to the best of its knowledge, these statements are based solely on facts and factors currently known to the company. Forward-looking statements should not be relied on as reliable information.
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.
View original version on businesswire.com: https://www.businesswire.com/news/home/20230515005511/en/
Leverage must be between 2 and 20
No data